Bladder cancer shows clear differences between men and women in terms of incidence, prognosis, and response to treatment, with growing evidence moving toward more gender-sensitive medicine. This cancer is not "only a male problem": it is a serious disease that deserves attention, research, and targeted strategies for both sexes.

Men have a three-four times higher risk of developing bladder cancer than women. Global estimates are about 9.6 new cases per 100,000 men and 2.4 per 100,000 women. In Italy, in 2020, out of 25,500 new patients, 20,500 were men and 5,000 were women. This trend is attributable to environmental factors (smoking and toxic substances), as well as possible biological variations.

Despite the lower incidence, women more often reach diagnosis at an advanced stage. The delay is often due to an initial misdiagnosis, such as urinary infection, which further delays appropriate investigations. Clinical studies confirm that women:

- They receive the diagnosis on average at age 75 compared with 71 years for men.
- They most frequently present advanced or infiltrating tumors.

This discrepancy results in lower survival among women. In advanced stages (III and IV), 5-year survival is about 15-16% versus 27-30% in men.

- Immunotherapy-a treatment that helps the immune system fight cancer. It seems to work better in men than in women. This is because, in many women, the tumor presents in a form that is less visible to the immune system, making the treatment less effective.
- Even with chemotherapy, there are differences: women may have different side effects or tolerate the drugs differently than men, but data on this point are still being studied.

These differences depend on so many factors: hormones, metabolism, tumor cell type, and even drug distribution in the body. That's why more and more doctors are asking for tailored treatments designed according to the patient's sex.

Experts stress the urgency of adopting a gender medicine approach:

- Ensure timely diagnoses, avoiding delays caused by misdiagnosis.
- Conduct clinical trials that sufficiently include women, to better understand differences in response to treatments.
- Develop specific protocols for male and female patients, optimizing efficacy and tolerability.

Bladder cancer is one of the most common urologic cancers, but it often does not receive the attention it deserves, especially when it affects women. Men are more affected in terms of numbers, but women face greater challenges: later diagnosis, less response to some therapies in advanced cases.

This is why it is essential to talk more about this cancer, raise awareness and promote medicine that is attentive to the differences between men and women.
Only in this way will we be able to ensure earlier diagnosis, more effective treatments and concretely improve the quality of life of people affected by this cancer.